Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
$17.80M
Dr. Sam Lee Ph.D.
13.00
Bothell, WA
Mar 12, 2018
-1.00
$-1.75
6.86
7.41
-12,450.00%
-1.00
0.00
1.03
124.35
7.41
-83.10%
-73.89%
Similar stocks (13)
Ikena Oncology, Inc.
IKNA
Akari Therapeutics, Plc
AKTX
Tempest Therapeutics, Inc.
TPST
RenovoRx, Inc.
RNXT
Pulmatrix, Inc.
PULM
Moleculin Biotech, Inc.
MBRX
Allarity Therapeutics, Inc.
ALLR
Kiromic BioPharma, Inc.
KRBP
Bio-Path Holdings, Inc.
BPTH
Quoin Pharmaceuticals, Ltd.
QNRX
Cyclacel Pharmaceuticals, Inc.
CYCC
Revelation Biosciences, Inc.
REVB
PaxMedica, Inc.
PXMD
ETF Exposure (8)
Dimensional U.S. Targeted Value ETF
DFAT
8.041999999999999e-5%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (13)
Ikena Oncology, Inc.
IKNA
Akari Therapeutics, Plc
AKTX
Tempest Therapeutics, Inc.
TPST
RenovoRx, Inc.
RNXT
Pulmatrix, Inc.
PULM
Moleculin Biotech, Inc.
MBRX
Allarity Therapeutics, Inc.
ALLR
Kiromic BioPharma, Inc.
KRBP
Bio-Path Holdings, Inc.
BPTH
Quoin Pharmaceuticals, Ltd.
QNRX
Cyclacel Pharmaceuticals, Inc.
CYCC
Revelation Biosciences, Inc.
REVB
PaxMedica, Inc.
PXMD
ETF Exposure (8)
Dimensional U.S. Targeted Value ETF
DFAT
8.041999999999999e-5%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%